These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21810837)

  • 21. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
    Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
    Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).
    Goossens H; Grabein B
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):257-64. PubMed ID: 16360549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temocillin and meropenem to discriminate resistance mechanisms leading to decreased carbapenem susceptibility with focus on OXA-48 in Enterobacteriaceae.
    Hartl R; Widhalm S; Kerschner H; Apfalter P
    Clin Microbiol Infect; 2013 May; 19(5):E230-2. PubMed ID: 23397897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
    Mushtaq S; Hope R; Warner M; Livermore DM
    J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
    Behera B; Mathur P; Das A; Kapil A
    Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended spectrum beta lactamase--mediated resistance among isolates of family Enterobacteriaceae.
    Deep ; Arora U
    Indian J Pathol Microbiol; 2007 Apr; 50(2):458-61. PubMed ID: 17883109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum β-lactamase and AmpC enzymes.
    Harris PN
    Semin Respir Crit Care Med; 2015 Feb; 36(1):56-73. PubMed ID: 25643271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
    Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
    Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.
    Ben-Ami R; Rodríguez-Baño J; Arslan H; Pitout JD; Quentin C; Calbo ES; Azap OK; Arpin C; Pascual A; Livermore DM; Garau J; Carmeli Y
    Clin Infect Dis; 2009 Sep; 49(5):682-90. PubMed ID: 19622043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2.
    Kanamori H; Yano H; Hirakata Y; Endo S; Arai K; Ogawa M; Shimojima M; Aoyagi T; Hatta M; Yamada M; Nishimaki K; Kitagawa M; Kunishima H; Kaku M
    J Antimicrob Chemother; 2011 Oct; 66(10):2255-62. PubMed ID: 21733965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
    Aslan AT; Akova M
    Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
    [No Abstract]   [Full Text] [Related]  

  • 35. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM; Hope R; Mushtaq S; Warner M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
    Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
    J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
    De Jongh R; Hens R; Basma V; Mouton JW; Tulkens PM; Carryn S
    J Antimicrob Chemother; 2008 Feb; 61(2):382-8. PubMed ID: 18070831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appearance of aac(6')-Ib-cr gene among extended-spectrum beta-lactamase-producing Enterobacteriaceae in a French hospital.
    Fihman V; Lartigue MF; Jacquier H; Meunier F; Schnepf N; Raskine L; Riahi J; Sanson-le Pors MJ; Berçot B
    J Infect; 2008 Jun; 56(6):454-9. PubMed ID: 18440645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms.
    Hutley EJ; Chand MA; Hounsome G; Kelsey MC
    J Infect; 2010 Apr; 60(4):308-9. PubMed ID: 20114062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.